Headache News

An integrated ambulatory care model that had infusion capacity for pediatric refractory headache appeared feasible and beneficial for these patients, according to a quality improvement study.

Healio Neurology’s most-viewed stories from 2021 highlight developments surrounding Aduhelm, the benefits of flavonoid on cognitive function and neurologic symptoms in COVID-19.

Aimovig appeared safe and effective for treating migraine with and without history of aura, according to results of a secondary analysis of randomized clinical trials published in JAMA Neurology.

The FDA has cleared an investigational new drug application for the start of a phase 2 study of TNX-1900, a nasal spray created to prevent migraine headaches.

A smartphone application may help clinicians detect concussion biomarkers, according to study results published in Life.

The FDA has designated a novel, noninvasive hypothermic therapy device designed to reduce concussion symptom severity as a breakthrough device, according to a press release.

Reyvow, Nurtec ODT and Ubrelvy were less efficacious than triptans for treating migraines, but these new pharmacologic agents correlated with fewer adverse events, according to a study published in JAMA Network Open.

Healio Neurology featured some of the major stories from the American Neurological Association Annual Meeting.

The likelihood that opioid treatment for common neurological conditions was initiated appeared to decrease with greater access to neurologists or other specialists who offered alternative pain treatment.

Many patients who experience migraine or headaches either hesitated or never sought medical care for their condition, according to data from two studies presented during the PAINWeek National Conference.